117 results match your criteria: "and the Texas Heart Institute[Affiliation]"

The Elephants Are Real.

Ann Thorac Surg

September 2024

Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and The Texas Heart Institute, 6770 Bertner Ave, Ste C330, Houston, TX 77030. Electronic address:

View Article and Find Full Text PDF

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.

N Engl J Med

September 2024

From the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York (R.S.R.); Université de Montréal, Montreal (D.G.), and Robarts Research Institute, London, ON (R.A.H.) - both in Canada; Baylor College of Medicine and the Texas Heart Institute - both in Houston (C.M.B.); Monash Victorian Heart Institute, Monash University, Melbourne, VIC (S.J.N.), and the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital, Perth (G.F.W.) - all in Australia; Lucas Research, Morehead City, NC (K.J.L.); and Arrowhead Pharmaceuticals, Pasadena, CA (J.S.M., R.Z., M.M., T.C., J.H.).

Background: Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. loss-of-function carriers have lower levels of triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and non-HDL cholesterol and a lower risk of atherosclerotic cardiovascular disease than noncarriers. Zodasiran is an RNA interference (RNAi) therapy targeting expression of in the liver.

View Article and Find Full Text PDF

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.

N Engl J Med

September 2024

From the Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); Borbánya Praxis, Nyíregyháza, Hungary (S.V.); Valley Clinical Trials, Northridge (M.A.), Arrowhead Pharmaceuticals, Pasadena (T.C., S.M., R.Z., M.M., J.H.), and the Stanford School of Medicine, Stanford (N.J.L.) - all in California; the Royal Adelaide Hospital, Adelaide, SA, Australia (P.C.); the Icahn School of Medicine at Mount Sinai, New York (R.S.R.); and the Department of Medicine, Université de Montréal and Ecogene-21, Quebec, QC, Canada (D.G.).

Background: Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non-high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol in triglyceride-rich lipoproteins. The metabolism and clearance of triglyceride-rich lipoproteins are down-regulated through apolipoprotein C3 (APOC3)-mediated inhibition of lipoprotein lipase.

Methods: We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 small interfering RNA, in patients with mixed hyperlipidemia (i.

View Article and Find Full Text PDF
Article Synopsis
  • - Obicetrapib is a new medication that lowers harmful LDL cholesterol and increases beneficial HDL cholesterol, potentially helping patients with high cholesterol levels who don’t respond to standard treatments.
  • - The BROADWAY and BROOKLYN trials are ongoing studies testing the effectiveness and safety of obicetrapib in patients with cardiovascular disease or genetic high cholesterol issues; over 2,500 participants are involved.
  • - Results from these trials, which will examine various cholesterol-related markers and safety concerns, are expected in 2024 and could support the use of obicetrapib in high-risk patient populations.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the impact of lipoprotein(a) (Lp[a]) on the risk of atherosclerotic cardiovascular disease (ASCVD) using data from 27,756 participants across five major U.S. studies, with a follow-up period averaging 21.1 years.
  • - Results indicate that higher Lp(a) levels correlate with increased risk of ASCVD events, especially among individuals with diabetes, with adjusted hazard ratios showing significant risk elevation at higher Lp(a) percentiles.
  • - The findings highlight that elevated Lp(a) independently predicts various cardiovascular events, including heart attacks and strokes, reinforcing its role as a genetic risk factor for ASCVD in diverse populations.
View Article and Find Full Text PDF

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.

N Engl J Med

May 2024

From the Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, (E.S.G.S.); Ionis Pharmaceuticals, Carlsbad (V.J.A., E.K.-P., T.A.P., S.X., S.T.), and the Divisions of Endocrinology and Metabolism (J.L.W.) and Cardiovascular Medicine (S.T.), Department of Medicine, University of California, San Diego, La Jolla - both in California; the Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (R.A.H.); the Department of Translational and Precision Medicine, Center for Rare Disorders of Lipid Metabolism, Sapienza University of Rome, Rome (M.A.); Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); the National Institute for Health Research and Wellcome Trust Clinical Research Facility, Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom (H.S.); and the Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (H.N.G.).

Article Synopsis
  • Familial chylomicronemia syndrome is a genetic condition that causes high triglyceride levels and can result in severe pancreatitis, which may be treated with the medication olezarsen that lowers triglycerides by reducing apolipoprotein C-III production.
  • A phase 3 clinical trial was conducted with 66 patients randomly assigned to receive either olezarsen (80 mg or 50 mg) or a placebo, with the goal of measuring changes in triglyceride levels and the incidence of acute pancreatitis over 6 months.
  • Results showed that the 80 mg dose significantly reduced triglyceride levels compared to placebo, while the 50 mg dose did not show significant improvement; both olezarsen doses resulted in reduced
View Article and Find Full Text PDF

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

J Am Coll Cardiol

April 2024

Université Paris-Cité, INSERM-UMR1148, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, French Alliance for Cardiovascular Trials, and Institut Universitaire de France, Paris, France.

Article Synopsis
  • - Elevated lipoprotein(a) (Lp[a]) levels increase the risk of cardiovascular events, even when low-density lipoprotein cholesterol is managed well; however, few treatments effectively address this issue.
  • - This research analyzed data from the REDUCE-IT trial to investigate how icosapent ethyl (IPE) may impact cardiovascular outcomes in patients with different Lp(a) levels.
  • - Results showed that higher baseline Lp(a) concentrations correlated with increased major adverse cardiovascular events (MACE), but IPE significantly reduced MACE consistently across various Lp(a) levels, indicating its potential benefits for patients regardless of Lp(a) status.
View Article and Find Full Text PDF

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.

Eur Heart J

April 2024

Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France.

View Article and Find Full Text PDF

Introduction: Given a looming shortage of surgeons and currently inadequate pipelines into our specialty for under-represented groups, there is an urgent need to identify and foster interest in young individuals who may have great potential as future surgeons. We aimed to explore the utility and feasibility of a novel survey instrument to identify high-school students well suited for careers in surgery based on personality profiling and grit.

Methods: An electronic screening tool was developed, combining components of the Myers-Briggs personality profile, the Big-Five Inventory 10, and the grit scale.

View Article and Find Full Text PDF

Gender Disparities in Cardiac Surgery Trials.

Ann Thorac Surg

November 2023

Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and The Texas Heart Institute, BCM 390, One Baylor Plaza, Houston, TX 77030. Electronic address:

View Article and Find Full Text PDF

Commentary: Board certification as a prerequisite for independent practice: Who is to say?

J Thorac Cardiovasc Surg

September 2022

Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and the Texas Heart Institute, Houston, Tex. Electronic address:

View Article and Find Full Text PDF

Predictors of High-Impact Articles in The Annals of Thoracic Surgery.

Ann Thorac Surg

December 2020

Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

Background: Altmetric scores are increasingly used as nontraditional metrics of scholarly impact that capture article social media attention. This study aims to characterize articles from The Annals of Thoracic Surgery that achieved the greatest online reach over a longitudinal period.

Methods: The 50 articles with the highest Altmetric scores published in The Annals of Thoracic Surgery for 2013, 2015, and 2017 were identified.

View Article and Find Full Text PDF

We compared the effects of linagliptin (Lina, a DPP4 inhibitor) and GLP-1 receptor activation by exenatide followed by exendin-4 in an infusion pump (EX) on infarct size (IS), post-infarction activation of the inflammasome and remodeling in wild-type (WT) and db/db diabetic mice. Mice underwent 30 min ischemia followed by 24 h reperfusion. IS was assessed by TTC.

View Article and Find Full Text PDF

Background: In the standard ECG display, limb leads are presented in a non-anatomical sequence: I, II, III, aVR, aVL, aVF. The Cabrera system is a display format which instead presents the limb leads in a cranial/left-to-caudal/right sequence, i.e.

View Article and Find Full Text PDF

Circulating blood cells and extracellular vesicles in acute cardioprotection.

Cardiovasc Res

June 2019

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4, Budapest 1089, Hungary.

During an ST-elevation myocardial infarction (STEMI), the myocardium undergoes a prolonged period of ischaemia. Reperfusion therapy is essential to minimize cardiac injury but can paradoxically cause further damage. Experimental procedures to limit ischaemia and reperfusion (IR) injury have tended to focus on the cardiomyocytes since they are crucial for cardiac function.

View Article and Find Full Text PDF

Background: Left-sided lesions (LSLs) account for an important fraction of severe congenital cardiovascular malformations (CVMs). The genetic contributions to LSLs are complex, and the mutations that cause these malformations span several diverse biological signaling pathways: TGFB, NOTCH, SHH, and more. Here, we use whole exome sequence data generated in 342 LSL cases to identify likely damaging variants in putative candidate CVM genes.

View Article and Find Full Text PDF

The adult mammalian heart is non-regenerative owing to the post-mitotic nature of cardiomyocytes. The neonatal mouse heart can regenerate, but only during the first week of life. Here we show that changes in the composition of the extracellular matrix during this week can affect cardiomyocyte growth and differentiation in mice.

View Article and Find Full Text PDF

Heme oxygenase-1 (HO-1) catalyzes the degradation of heme, which may be involved in the pathogenesis of AKI. Length polymorphisms in the number of GT dinucleotide repeats in the HO-1 gene (HMOX1) promoter inversely associate with HMOX1 mRNA expression. We analyzed the association between allelic frequencies of GT repeats in the HMOX1 gene promoter and postoperative AKI in 2377 white patients who underwent cardiac surgery with cardiopulmonary bypass.

View Article and Find Full Text PDF

Competition: Perspiration to inspiration "Aut inveniam viam aut faciam".

J Thorac Cardiovasc Surg

November 2016

Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, and the Texas Heart Institute, Houston, Tex. Electronic address:

View Article and Find Full Text PDF

Rationale: Acute kidney injury is a common and severe complication of critical illness and cardiac surgery. Despite significant attempts at developing treatments, therapeutic advances to attenuate acute kidney injury and expedite recovery have largely failed.

Objectives: Identifying genetic loci associated with increased risk of acute kidney injury may reveal novel pathways for therapeutic development.

View Article and Find Full Text PDF

Shared Genetic Risk Factors of Intracranial, Abdominal, and Thoracic Aneurysms.

J Am Heart Assoc

July 2016

Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

Background: Intracranial aneurysms (IAs), abdominal aortic aneurysms (AAAs), and thoracic aortic aneurysms (TAAs) all have a familial predisposition. Given that aneurysm types are known to co-occur, we hypothesized that there may be shared genetic risk factors for IAs, AAAs, and TAAs.

Methods And Results: We performed a mega-analysis of 1000 Genomes Project-imputed genome-wide association study (GWAS) data of 4 previously published aneurysm cohorts: 2 IA cohorts (in total 1516 cases, 4305 controls), 1 AAA cohort (818 cases, 3004 controls), and 1 TAA cohort (760 cases, 2212 controls), and observed associations of 4 known IA, AAA, and/or TAA risk loci (9p21, 18q11, 15q21, and 2q33) with consistent effect directions in all 4 cohorts.

View Article and Find Full Text PDF

Background: Aortic dissection (AoD) is a serious complication of thoracic aortic aneurysm (TAA). Relative risk for AoD in relation to TAA etiology, incidence, and pattern after prophylactic TAA surgery are poorly understood.

Objectives: This study sought to determine the incidence, pattern, and relative risk for AoD among patients with genetically associated TAA.

View Article and Find Full Text PDF